| This week's sponsor is Navitas. | | | |
Top Stories Monday, July 18, 2016 Third Rock-backed Jounce Therapeutics has done its first major deal with a biopharma. Its new immuno-oncology partnership with Celgene could be worth up to $2.6 billion. Monday, July 18, 2016 Small molecules to control gene expression are an idea whose time has come--at least Third Rock Ventures thinks so. Now, the firm is ready to launch the fruit of that labor, Fulcrum Therapeutics, with a rich Series A round of $55 million. Tuesday, July 19, 2016 Germany’s Merck KGaA has announced new plans to create a “major hub” for its North American life science business as it prepares to build a new campus in Burlington, MA, but will be leaving its former Billerica base. Tuesday, July 19, 2016 Ionis Pharmaceuticals has sold the rights to its early-stage GI autoimmune disease candidate IONIS-JBI1-2.5Rx to Janssen as the company announces strong growth for Q2 and an uptick in R&D spend. Tuesday, July 19, 2016 Poxel has hit pause on its plan to IPO on Nasdaq. The Merck Serono spinout indicated its interest in a Nasdaq IPO earlier this year, but has now opted to postpone the plan in favor of using its Euronext listing to generate the €26.5 million it needs to advance its Type 2 diabetes drug into Phase III in Japan. | | | French biotech Ipsen has seen the EMA accept its application for telotristat etiprate for the treatment of carcinoid syndrome caused by neuroendocrine tumors. Statement Cambridge, MA-based Quartet Medicine has appointed former FORUM Pharmaceuticals CSO Gerhard Koenig as its new CEO. Release Sweden’s Hansa Medical has acquired U.K.-based Immago Biosystems, a University of Oxford oncology spinout. Statement Eisai and marketing partner Arena Pharmaceuticals have seen an FDA approval for a longer-acting form of their anti-obesity drug Belviq XR (lorcaserin). Release |
Resources Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Download now. Sponsored by: Speid & Associates, Inc. Do you have what it takes? Drug Development training does not have to be boring. The Drug Development Boot CampTM trains experienced researchers and drug developers in all major aspects of drug development, using an accelerated learning and total immersion approach. Click here to website. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain | 